133 related articles for article (PubMed ID: 18500692)
1. Novel small molecule inhibitors for prostate-specific antigen.
Koistinen H; Wohlfahrt G; Mattsson JM; Wu P; Lahdenperä J; Stenman UH
Prostate; 2008 Aug; 68(11):1143-51. PubMed ID: 18500692
[TBL] [Abstract][Full Text] [Related]
2. Antiangiogenic properties of prostate-specific antigen (PSA).
Mattsson JM; Laakkonen P; Stenman UH; Koistinen H
Scand J Clin Lab Invest; 2009; 69(4):447-51. PubMed ID: 19551556
[TBL] [Abstract][Full Text] [Related]
3. Structural characterization and anti-angiogenic properties of prostate-specific antigen isoforms in seminal fluid.
Mattsson JM; Valmu L; Laakkonen P; Stenman UH; Koistinen H
Prostate; 2008 Jun; 68(9):945-54. PubMed ID: 18386289
[TBL] [Abstract][Full Text] [Related]
4. Peptides binding to prostate-specific antigen enhance its antiangiogenic activity.
Mattsson JM; Närvänen A; Stenman UH; Koistinen H
Prostate; 2012 Oct; 72(14):1588-94. PubMed ID: 22430591
[TBL] [Abstract][Full Text] [Related]
5. Prostate-specific antigen (PSA) protein does not affect growth of prostate cancer cells in vitro or prostate cancer xenografts in vivo.
Denmeade SR; Litvinov I; Sokoll LJ; Lilja H; Isaacs JT
Prostate; 2003 Jun; 56(1):45-53. PubMed ID: 12746846
[TBL] [Abstract][Full Text] [Related]
6. Mechanistic insights into the inhibition of prostate specific antigen by beta-lactam class compounds.
Singh P; Williams SA; Shah MH; Lectka T; Pritchard GJ; Isaacs JT; Denmeade SR
Proteins; 2008 Mar; 70(4):1416-28. PubMed ID: 17894328
[TBL] [Abstract][Full Text] [Related]
7. Recombinant prostate specific antigen inhibits angiogenesis in vitro and in vivo.
Fortier AH; Holaday JW; Liang H; Dey C; Grella DK; Holland-Linn J; Vu H; Plum SM; Nelson BJ
Prostate; 2003 Aug; 56(3):212-9. PubMed ID: 12772191
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and preliminary biological evaluation of 2,3-dihydro-3-hydroxymethyl-1,4-benzoxazine derivatives.
Jiao PF; Zhao BX; Wang WW; He QX; Wan MS; Shin DS; Miao JY
Bioorg Med Chem Lett; 2006 Jun; 16(11):2862-7. PubMed ID: 16563757
[TBL] [Abstract][Full Text] [Related]
9. Gene expression changes associated with the anti-angiogenic activity of kallikrein-related peptidase 3 (KLK3) on human umbilical vein endothelial cells.
Mattsson JM; Laakkonen P; Kilpinen S; Stenman UH; Koistinen H
Biol Chem; 2008 Jun; 389(6):765-71. PubMed ID: 18627292
[TBL] [Abstract][Full Text] [Related]
10. Evidence that the prostate-specific antigen (PSA)/Zn2+ axis may play a role in human prostate cancer cell invasion.
Ishii K; Otsuka T; Iguchi K; Usui S; Yamamoto H; Sugimura Y; Yoshikawa K; Hayward SW; Hirano K
Cancer Lett; 2004 Apr; 207(1):79-87. PubMed ID: 15050736
[TBL] [Abstract][Full Text] [Related]
11. [Design and activity determination of small molecular inhibitors of integrin alphavbeta3].
Ji Q; Zhou Y; Peng H; Huang N; Qi J; Xiong DS; Gao YD; Yang M; Yang CZ
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2007 Jun; 29(3):347-52. PubMed ID: 17633460
[TBL] [Abstract][Full Text] [Related]
12. Selective recognition of enzymatically active prostate-specific antigen (PSA) by anti-PSA monoclonal antibodies.
Michel S; Collomb-Clerc E; Geourjon C; Charrier JP; Passagot J; Courty Y; Deléage G; Jolivet-Reynaud C
J Mol Recognit; 2005; 18(3):225-35. PubMed ID: 15593306
[TBL] [Abstract][Full Text] [Related]
13. Presence and enzymatic activity of prostate-specific antigen in archival prostate cancer samples.
Vukmirovic-Popovic S; Escott NG; Duivenvoorden WC
Oncol Rep; 2008 Oct; 20(4):897-903. PubMed ID: 18813833
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of the enzymatic activity of prostate-specific antigen by boric acid and 3-nitrophenyl boronic acid.
Gallardo-Williams MT; Maronpot RR; Wine RN; Brunssen SH; Chapin RE
Prostate; 2003 Jan; 54(1):44-9. PubMed ID: 12481254
[TBL] [Abstract][Full Text] [Related]
15. Development of hormone-dependent prostate cancer models for the evaluation of inhibitors of 17beta-hydroxysteroid dehydrogenase type 3.
Day JM; Tutill HJ; Foster PA; Bailey HV; Heaton WB; Sharland CM; Vicker N; Potter BV; Purohit A; Reed MJ
Mol Cell Endocrinol; 2009 Mar; 301(1-2):251-8. PubMed ID: 18786604
[TBL] [Abstract][Full Text] [Related]
16. High-throughput cell-based screening of 4910 known drugs and drug-like small molecules identifies disulfiram as an inhibitor of prostate cancer cell growth.
Iljin K; Ketola K; Vainio P; Halonen P; Kohonen P; Fey V; Grafström RC; Perälä M; Kallioniemi O
Clin Cancer Res; 2009 Oct; 15(19):6070-8. PubMed ID: 19789329
[TBL] [Abstract][Full Text] [Related]
17. Development of peptides specifically modulating the activity of KLK2 and KLK3.
Koistinen H; Närvänen A; Pakkala M; Hekim C; Mattsson JM; Zhu L; Laakkonen P; Stenman UH
Biol Chem; 2008 Jun; 389(6):633-42. PubMed ID: 18627344
[TBL] [Abstract][Full Text] [Related]
18. Characterization of prostate-specific antigen binding peptides selected by phage display technology.
Ferrieu-Weisbuch C; Michel S; Collomb-Clerc E; Pothion C; Deléage G; Jolivet-Reynaud C
J Mol Recognit; 2006; 19(1):10-20. PubMed ID: 16312021
[TBL] [Abstract][Full Text] [Related]
19. Regulation of PSA secretion and survival signaling by calcium-independent phopholipase A(2)beta in prostate cancer cells.
Nicotera TM; Schuster DP; Bourhim M; Chadha K; Klaich G; Corral DA
Prostate; 2009 Sep; 69(12):1270-80. PubMed ID: 19475654
[TBL] [Abstract][Full Text] [Related]
20. Anti-angiogenic activity of PSA-derived peptides.
Chadha KC; Nair B; Godoy A; Rajnarayanan R; Nabi E; Zhou R; Patel NR; Aalinkeel R; Schwartz SA; Smith GJ
Prostate; 2015 Sep; 75(12):1285-99. PubMed ID: 25963523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
